Neoadjuvant cisplatin and doxorubicin in locally advanced triple negative breast cancer
| Autor: | Quratul Ain Hashmi, Famya Abdullah, Abdul Mateen, Rab Nawaz Maken, Allah Rakha Adil, Arif Moin Duraishi |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Cisplatin
Oncology Cancer Research medicine.medical_specialty education.field_of_study Chemotherapy medicine.diagnostic_test business.industry medicine.medical_treatment Population medicine.disease Response Evaluation Criteria in Solid Tumors Internal medicine Biopsy medicine Doxorubicin business education Progressive disease Triple-negative breast cancer medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 34:e12511-e12511 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.e12511 |
| Popis: | e12511Background: Triple negative breast cancer (TNBC) is common in Pakistan and presents in advanced stage due to aggressive behavior. Neoadjuvant chemotherapy (NACT) is usual therapy before local surgical treatment. Choice of chemotherapy (CT) is in a process of refinement for these patients. Platin based CT has shown promising results. Due to limited resources, cost of drugs does matter for treating poors. We have tested inexpensive CT with cisplatin and doxorubicin to see outcome in this population. Methods: All patients had biopsy proven locally advanced invasive TNBC without evidence of metastatic disease on imaging (CT chest, abdomen and bone scan). All patients were planned for treatment with cisplatin (60 mg/m2) and doxorubicin (50 mg/m2) every three weekly for six cycles. The patients were evaluated after every two cycles for response using Response Evaluation Criteria in Solid Tumors (RECIST). A patient showing progressive disease (PD) or having developed grade III or IV toxicity (according to ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|